The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

China is one of the countries with the highest incidence of gastric cancer. There are differences in epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selection between gastric cancer patients from the Eastern and Western countries. Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients. The Chinese Society of Clinical Oncology (CSCO) arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile, discuss, and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad. By referring to the opinions of industry experts, taking into account of regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted experts’ consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes. This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis, comprehensive treatment, and follow-up visits for gastric cancer.

Related collections

Most cited references 126

Record: found
Abstract: not found
Article: not found

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E.C. Smyth, M Verheij, W Allum … (2016)

0 comments Cited 611 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

David Cunningham, Naureen Starling, Sheela Rao … (2008)

We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer. In a two-by-two design, we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil (EOF) or capecitabine (EOX). The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin. For the capecitabine-fluorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); for the oxaliplatin-cisplatin comparison, the hazard ratio for the oxaliplatin group was 0.92 (95% CI, 0.80 to 1.10). The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 1.23. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.9 months, 9.9 months, 9.3 months, and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4%, and 46.8%, respectively. In the secondary analysis, overall survival was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; P=0.02). Progression-free survival and response rates did not differ significantly among the regimens. Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy. Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883 [controlled-trials.com].). Copyright 2008 Massachusetts Medical Society.

0 comments Cited 600 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Marc Ychou, Valérie Boige, Jean-Pierre Pignon … (2011)

After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma. Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS. Compared with the S group, the CS group had a better OS (5-year rate 38% v 24%; hazard ratio [HR] for death: 0.69; 95% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34% v 19%; HR, 0.65; 95% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P < .01). Perioperative chemotherapy significantly improved the curative resection rate (84% v 73%; P = .04). Grade 3 to 4 toxicity occurred in 38% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups. In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.

0 comments Cited 589 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Feng-Hua Wang: wangfh@sysucc.org.cn

Lin Shen: linshenpku@163.com

Jin Li: lijin@csco.org.cn

Zhi-Wei Zhou: zhouzhiwei@sysucc.org.cn

Han Liang: tjlianghan@126.com

Xiao-Tian Zhang: zhangxiaotianmed@163.com

Lei Tang: terrytang@163.com

Yan Xin: yxin@mail.cmu.edu.cn

Jing Jin: jingjing1025@163.com

Yu-Jing Zhang: zhangyj@sysucc.org.cn

Xiang-Lin Yuan: xlyuan1020@163.com

Tian-Shu Liu: liu.tianshu@zs-hospital.sh.cn

Guo-Xin Li: gzliguoxin@163.com

Qi Wu: wuqi1973@163.com

Hui-Mian Xu: xuhuimian@126.com

Jia-Fu Ji: jiafuj@hotmail.com

Yuan-Fang Li: liyuanf@sysucc.org.cn

Xin Wang: berylwx2000@163.com

Shan Yu: 0456233@fudan.edu.cn

Hao Liu: liuhaofbi@163.com

Wen-Long Guan: guanwenlong@sysucc.org.cn

Rui-Hua Xu: xurh@sysucc.org.cn

Journal

Journal ID (nlm-ta): Cancer Commun (Lond)

Journal ID (iso-abbrev): Cancer Commun (Lond)

Title: Cancer Communications

Publisher: BioMed Central (London )

ISSN (Electronic): 2523-3548

Publication date (Electronic): 18 March 2019

Publication date PMC-release: 18 March 2019

Publication date Collection: 2019

Volume: 39

Electronic Location Identifier: 10

Affiliations

[1 ]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060 Guangdong P. R. China

[2 ]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142 P. R. China

[3 ]ISNI 0000000123704535, GRID grid.24516.34, Department of Oncology, , Shanghai East Hospital, Tongji University School of Medicine, ; Shanghai, 200120 P. R. China

[4 ]Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060 Guangdong P. R. China

[5 ]ISNI 0000 0004 1798 6427, GRID grid.411918.4, Department of Gastric Cancer, , Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center of Cancer, Tianjin’s Clinical Research Cancer for Cancer, Key Laboratory of Cancer Prevention and Therapy, ; Tianjin, 300060 P. R. China

[6 ]Medical Imaging Department, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142 P. R. China

[7 ]GRID grid.412636.4, Pathology Laboratory of Gastrointestinal Tumor, , The First Hospital of China Medical University, ; Shenyang, 110001 Liaoning P. R. China

[8 ]ISNI 0000 0000 9889 6335, GRID grid.413106.1, Department of Radiation Oncology, , National Cancer Center, China and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, 100021 P. R. China

[9 ]Department of Radiotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060 Guangdong P. R. China

[10 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Department of Medical Oncology, , Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, ; Wuhan, 430030 Hubei P. R. China

[11 ]ISNI 0000 0004 1755 3939, GRID grid.413087.9, Department of Medical Oncology, , Zhongshan Hospital Affiliated to Fudan University, ; Shanghai, 200032 P. R. China

[12 ]GRID grid.416466.7, Department of General Surgery, , Nanfang Hospital Affiliated to Southern Medical University, ; Guangzhou, 510515 Guangdong P. R. China

[13 ]Department of Endoscopy Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142 P. R. China

[14 ]GRID grid.412636.4, Department of Surgical Oncology, , The First Hospital of China Medical University, ; Shenyang, 110001 Liaoning P. R. China

Article

Publisher ID: 349

DOI: 10.1186/s40880-019-0349-9

PMC ID: 6423835

PubMed ID: 30885279

SO-VID: 69be4033-85fc-44e4-a214-8e39f8495fb1

License:

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

History

Date received : 25 January 2019

Date accepted : 1 February 2019

Custom metadata

Keywords: chinese society of clinical oncology (csco),gastric cancer,diagnosis,surgery,neoadjuvant,adjuvant,radiotherapy,chemotherapy,targeted therapy,immunotherapy

Data availability:

Keywords: chinese society of clinical oncology (csco), gastric cancer, diagnosis, surgery, neoadjuvant, adjuvant, radiotherapy, chemotherapy, targeted therapy, immunotherapy

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 126

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Author and article information

Contributors

Journal

Affiliations

Article

History

Categories

Custom metadata

Comments

Comment on this article

Similar content 165

Cited by 224

Most referenced authors 3,335